Risperdal Trials Pick Up Speed After Patients Claim Serious Side Effects
A growing number of lawsuits involving allegations of serious injuries due to Risperdal have been filed as more patients come forward with adverse event reports. Mass tort cases have developed into numerous Risperdal trials against Johnson & Johnson and subsidiary companies.
Risperdal, a popular medication used to treat schizophrenia and bipolar disorder, first received FDA approval in 1993. It was later approved as an adolescent antipsychotic in 2006 for those patients who had irritability tied to autism. Janssen Pharmaceuticals, owned by Johnson & Johnson, manufactures the medication, and both companies have been named in Risperdal trials as public concern over the drug’s side effects continues to grow.
Although side effects are possible with Risperdal as with many other drugs, one of the primary allegations from plaintiffs in Risperdal trials is that men develop breast tissue, a condition known as gynecomastia. The men in these cases claim that neither they nor their doctors were fully warned about the risks of the medication.
As more public interest and media coverage of the Risperdal trials have occurred, the number of people filing cases has also increased. In the first half of 2017, for example, there were approximately 2,000 cases associated with Risperdal. That number jumped to 6,000 just a few months later. The biggest mass tort litigation is currently in the Philadelphia court system, and at least 600 more cases have been filed there since June of 2017.
The court systems have not yet developed a comprehensive plan to deal with the surge in litigation for Risperdal trials, but the rising number of plaintiffs could put a burden on the court dockets if more people continue to come forward with claims of gynecomastia.
Paperwork in currently Risperdal trials argue that the drug might increase prolactin levels for young men taking it. This hormone stimulates breast development in woman. In addition to the emotional challenges presented to young men who develop gynecomastia, the same patients might also struggle with side effects like nipple discharge or pain. A 2006 study in the Journal of Clinical Psychopharmacology drew a strong connection between Risperdal and the development of prolactin.
Some Risperdal trials have already ended in settlements or jury verdicts for the plaintiffs. One Philadelphia-based case, for example, set the record with a verdict of more than $75 million, some of which was assessed in delay damages. It is believed that some of the increase in these Risperdal trials as of late was caused by Johnson & Johnson’s own decision to terminate the “on-hold” status of the statute of limitations, encouraging other victims to come forward and file their claims over the summer.
Patients affected by Risperdal, especially young men who developed gynecomastia as a result, may be entitled to recover compensation for their injuries by filing a lawsuit.
The lawyers at McDonald Worley are currently evaluating these claims and speaking with victims who may have been harmed by the drug. Schedule a FREE consultation today to learn more about your rights.